GlassScriptPhysician profile
Macy S Bailey
NPI 1760126700
$2,497.58
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $664 · 2023: $1,235 · 2024: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.20 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $362.13 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $325.16 | 2022-2024 | Relistor, Xifaxan |
| Otsuka America Pharmaceutical, INC. | $184.84 | 2022-2024 | Rexulti, Abilify Maintena |
| Dexcom, INC. | $167.93 | 2022-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $82.71 | 2024 | Voquezna |
| Mylan Specialty L.P. | $78.22 | 2022-2024 | Yupelri |
| Pfizer INC. | $76.46 | 2023 | |
| Exact Sciences Corporation | $69.60 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $58.51 | 2022-2023 | Mounjaro, Emgality, Jardiance |
| Amgen INC. | $52.50 | 2022 | |
| Astellas Pharma US INC | $51.63 | 2022-2023 | Myrbetriq |
| Axsome Therapeutics, INC. | $47.79 | 2024 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $46.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.31 | 2022-2023 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $38.03 | 2023-2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $33.61 | 2023-2024 | Trintellix |
| Lifescan, INC. | $30.29 | 2023 | |
| Cequr Corporation | $29.28 | 2024 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $26.13 | 2022-2023 | |
| Nevro Corp. | $23.81 | 2024 | Senza |
| Medicomp INC | $22.15 | 2023 | Telepatch Cardiac Monitor |
| Nestle Healthcare Nutrition INC. | $19.94 | 2022 | |
| Indivior INC. | $18.36 | 2024 | Sublocade |
| Lundbeck LLC | $18.02 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $16.77 | 2023 | |
| Ironwood Pharmaceuticals, INC | $14.34 | 2022 | |
| Hikma Pharmaceuticals USA | $14.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Macy Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.